# Richard Furie

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-furie/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,714 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 72 |
| i10-index | 172 |
| Last Known Institution | Northwell Health |
| OpenAlex ID | https://openalex.org/A5076651506 |
| ORCID iD | 0000-0001-6712-1585 |
| Works | 384 |

## Researcher papers

Showing 12 of 17.

- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-patients-with-active-proliferative-lupus/)
- [Trial of Anifrolumab in Active Systemic Lupus Erythematosus](https://scholariq.org/papers/trial-of-anifrolumab-in-active-systemic-lupus-erythematosus/)
- [Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis](https://scholariq.org/papers/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis/)
- [EULAR recommendations for the management of systemic lupus erythematosus: 2023 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023/)
- [Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus](https://scholariq.org/papers/anifrolumab-an-anti-interferon-receptor-monoclonal-antibody-in-moderate-to/)
- [The immune cell landscape in kidneys of patients with lupus nephritis](https://scholariq.org/papers/the-immune-cell-landscape-in-kidneys-of-patients-with-lupus-nephritis/)
- [A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis](https://scholariq.org/papers/a-short-course-of-bg9588-anti-cd40-ligand-antibody-improves-serologic-activity/)
- [A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus](https://scholariq.org/papers/a-phase-ii-randomized-double-blind-placebo-controlled-dose-ranging-study-of/)
- [Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial](https://scholariq.org/papers/baricitinib-for-systemic-lupus-erythematosus-a-double-blind-randomised-placebo/)
- [Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study](https://scholariq.org/papers/sifalimumab-an-anti-interferon-monoclonal-antibody-in-moderate-to-severe/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Researcher university

- [Northwell Health](https://scholariq.org/institutions/northwell-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.